Heartbeam, Inc. - Common Stock (OQ:BEAT)

Business Focus: N/A

Apr 09, 2024 08:31 am ET

HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced new data demonstrating that applying the company’s artificial intelligence (AI) algorithms to vectorcardiography (VCG) showed considerably improved performance in the detection of atri

Mar 20, 2024 04:05 pm ET

HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.

Mar 14, 2024 08:31 am ET

First Patients Enrolled in Pivotal Study Evaluating HeartBeam’s AIMIGo™ System for Synthesizing a 12-Lead ECG

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has enrolled the first patients in the VALID-ECG (Clinical Validation of the AIMIGo 12-Lead ECG Synthesis Software for Arrhythmia Detection) pivotal study. The first patients were enrolled at Atlanta Heart Specialists, a top cardiology physician practice in Atlanta, GA.

Mar 07, 2024 08:31 am ET

HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has received two new patents on its core vectorelectrocardiography (VECG) technology from the United States Patent and Trademark Office. HeartBeam now has 14 issued and allowed US patents and 4 international patents for its VECG technology which collects 3D signals of the heart and converts them into a 12-lead ECG.

Mar 05, 2024 08:31 am ET

HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, will hold a conference call on Wednesday March 20, 2024 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2023, and will be providing regulatory updates, reviewing ongoing initiatives, and anticipated 2024 milestones. A press release detailing these results will be issued prior to the call.

Dec 14, 2023 08:31 am ET

HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced significant developments for the use of artificial intelligence (AI) applied to its proprietary vectorelectrocardiography (VECG) technology, including the addition of new leadership and advisory roles. By coupling machine learning methods with the company’s VECG technology, HeartBeam aims to provide physicians with unprecedented diagnostic and prognostic insights about cardiac health that it believes will exceed the information pro

Nov 14, 2023 04:01 pm ET

HeartBeam Reports Third Quarter 2023 Financial Results

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, has reported its financial and operational results for the third quarter ended September 30, 2023.

Nov 09, 2023 08:31 am ET

HeartBeam Announces Expansion of Its Scientific Advisory Board

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.

Nov 07, 2023 08:31 am ET

HeartBeam Granted Third US Patent for 12-Lead Extended Wear Patch for Detecting Heart Attacks and Complex Cardiac Arrythmias

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size, portable 3D-vector electrocardiogram (VECG) platform that is always with the patient, allowing for the creation of rich data for AI, today announced that the United States Patent and Trademark Office has granted a new patent on HeartBeam’s novel VECG platform.

Oct 31, 2023 08:31 am ET

HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, will hold a conference call on Tuesday November 14, 2023 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2023, and will be reviewing recent announcements, ongoing initiatives, and anticipated 2024 milestones. A press release detailing these results will be issued prior to the call.

Sep 27, 2023 08:05 am ET

Implicity Expands Senior Leadership Team with New U.S. Chief Commercial Officer

Medical device industry veteran, Jon Hunt, will lead the next phase of growth for Implicity as demand for remote cardiac monitoring and data management solutions soars

Sep 26, 2023 08:31 am ET

HeartBeam Appoints Richa Gujarati and Pooja Chatterjee to Senior Management Team

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, has appointed Richa Gujarati as Senior Vice President, Product, and Pooja Chatterjee as Vice President, Clinical.

Sep 21, 2023 09:35 am ET

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand...

Aug 10, 2023 04:01 pm ET

HeartBeam Reports Second Quarter 2023 Financial Results

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, has reported its financial and operational results for the second quarter ended June 30, 2023.

Aug 09, 2023 08:31 am ET

HeartBeam Announces Publication of Foundational Study on the Detection of Heart Attacks

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the publication of a foundational study demonstrating the ability of its VECG platform to detect the presence of coronary artery blockages.

Aug 08, 2023 08:31 am ET

HeartBeam Appoints Deborah Castillo as Vice President of Regulatory Affairs

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the appointment of Deborah Castillo, PhD, as Vice President of Regulatory Affairs.

Jul 27, 2023 08:31 am ET

HeartBeam to Host Second Quarter 2023 Results Conference Call on Thursday August 10, 2023 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, will hold a conference call on Thursday August 10, 2023 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2023, and will be reviewing recent announcements, ongoing initiatives, and key 2023 milestones. A press release detailing these results will be issued prior to the call.

Jul 26, 2023 08:31 am ET

HeartBeam Appoints Dr. Michael R. Jaff to the Board of Directors

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, today announced the appointment of Michael R. Jaff, DO to its board of directors, effective as of July 24, 2023. This appointment brings the number of HeartBeam board members to eight.

Jun 08, 2023 08:31 am ET

HeartBeam Appoints Ken Nelson and Mark Strome to the Board of Directors

May 30, 2023 08:00 am ET

HeartBeam Enters into Strategic Alliance Agreement with Samsung

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, today announced that it has entered into a Strategic Alliance Agreement (SAA) with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam acquired the assets of LIVMOR earlier this year.

May 25, 2023 08:31 am ET

HeartBeam Announces Automated Cardiac Detection Patent Granted for HeartBeam AIMIGo™ System

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform intended for patient use at home, today announced it has received a notice of allowance from The United States Patent and Trademark Office for a key patent relating to the initial AI capability in the form of an expert system for its HeartBeam AIMIGoTM System. The patent is entitled, “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment.”

May 18, 2023 08:31 am ET

HeartBeam Announces FDA Submission of HeartBeam AIMIGo™ VECG System

May 11, 2023 04:01 pm ET

HeartBeam Reports First Quarter 2023 Financial Results

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has reported its financial and operational results for the first quarter ended March 31, 2023.

May 03, 2023 08:31 am ET

HeartBeam Completes $25 Million Capital Raise and Updates 2023 Strategic Focus and Financial Guidance

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform to help physicians detect heart attacks anytime, anywhere as well as diagnose other common heart conditions today announced closing of its secondary offering of 16,666,666 shares of HeartBeam’s common stock. This financing will allow HeartBeam to fund its upcoming clinical and regulatory milestones related to its HeartBeam AIMIGo™ system and prepare for commercialization in 2024.

Mar 16, 2023 04:01 pm ET

HeartBeam Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 14, 2023 08:31 am ET

HeartBeam Announces Acquisition of LIVMOR Assets

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today announced the strategic acquisition of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system of critical physiological biomarkers. The acquisition extends HeartBeam’s reach in remote monitoring and detection with full ownership of an existing cutting-edge FDA-cleared product.

Mar 08, 2023 08:31 am ET

HeartBeam Announces Senior Leadership Change

During his tenure, Dr. Hunt has made significant contributions to HeartBeam’s business efforts, leading numerous initiatives and introductions with partner manufacturing and technology companies and health systems providers.

Mar 02, 2023 08:31 am ET

HeartBeam to Host Fourth Quarter and Full Year 2022 Results Conference Call on Thursday March 16, 2023 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, will hold a conference call on Thursday March 16, 2023 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2022, and will be reviewing recent announcements, ongoing initiatives, and key 2023 milestones. A press release detailing these results will be issued prior to the call.

Jan 24, 2023 08:31 am ET

HeartBeam Appoints Robert Eno as President

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced today the appointment of Robert Eno to the newly created position of President. Eno has a proven track record of developing markets and commercializing disruptive medical technologies. He will play a key role in the strategic direction, commercialization efforts, and day-to-day operations for the HeartBeam AIMI™ and HeartBeam AIMIGo™ platforms.

Jan 05, 2023 08:31 am ET

HeartBeam Granted European Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the European Patent Office. This patent offers protection for HeartBeam’s flagship technology in multiple countries in Europe and has been validated in France, Germany, Netherlands and the United Kingdom. The innovation opens the pathway for a patient to record a set of signa

Dec 29, 2022 08:31 am ET

HeartBeam Issues Shareholder Letter and Provides Corporate Update

Dec 07, 2022 08:31 am ET

HeartBeam Partners with Evolve Manufacturing to Build HeartBeam AIMIGoTM 12-Lead 3D Vector Electrocardiogram Device

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today announced it has signed an agreement (the “Agreement”) with Evolve Manufacturing Technologies (“Evolve”), a contract medical device manufacturing company, to build the credit card-sized AIMIGo 3D vector electrocardiogram (VECG) recording device that provides a 12 lead ECG readout for remote heart attack detection. Under the terms of the Agreement, HeartBeam will leverage Evolve’s manufacturing a

Nov 16, 2022 08:45 am ET

New HeartBeam Patent for 12-Lead Electrocardiogram (ECG) Smartwatch-based Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced today that its patent for a 12-lead electrocardiogram (ECG) smartwatch-based monitor intended for detection of heart attacks and complex cardiac arrhythmias was allowed by the United States Patent and Trademark Office. The innovation builds on HeartBeam’s growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting.

Nov 10, 2022 04:01 pm ET

HeartBeam Reports Third Quarter 2022 Financial Results

Oct 25, 2022 08:31 am ET

HeartBeam to Host Third Quarter 2022 Results Conference Call on Thursday November 10, 2022 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, will hold a conference call on Thursday November 10, 2022 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2022, and will be reviewing recent announcements, ongoing initiatives, and key 2022 and anticipated 2023 milestones. A press release detailing these results will be issued prior to the call.

Oct 13, 2022 08:31 am ET

HeartBeam to Present at LD Micro Main Event XV Conference

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, will present at the LD Micro Main Event XV Conference being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA on October 25-27, 2022.

Oct 11, 2022 08:31 am ET

HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced the appointment of Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer. In addition to his world-renowned expertise in interventional cardiology, Dr. Fitzgerald is an accomplished inventor, entrepreneur, and investment fund founder.

Oct 06, 2022 09:36 am ET

Thinking about buying stock in Heartbeam, Provention Bio, Pinterest, Quantum-Si, or Palantir Technologies?

NEW YORK, Oct. 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BEAT, PRVB, PINS, QSI, and PLTR.

Oct 06, 2022 08:31 am ET

HeartBeam Broadens Product Portfolio Pipeline with Smartwatch Connectivity Enablement for 24/7 Heart Monitoring Solution

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today the expansion of its product portfolio pipeline to serve the growing cardiac device wearable technology market by bringing clinically relevant diagnostic information to patients and clinicians. The product pipeline advancement allows for the addition of arrhythmia detection capabilities to address the multibillion-dollar global market for atrial fibrillation and other arrhythmia monitoring.

Sep 29, 2022 08:31 am ET

HeartBeam to Present at Upcoming Investor Conferences

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, will present at the Dawson James Small Cap Growth Conference being held at the Wyndham Grand Hotel in Jupiter, FL on October 12, 2022, and The ThinkEquity Conference taking place at the Mandarin Oriental Hotel in New York City on October 26, 2022.

Sep 28, 2022 09:54 am ET

Thinking about buying stock in Frontier Communications, Edgio, Alaunos Therapeutics, Heartbeam, or Blue Apron?

NEW YORK , Sept. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FYBR, EGIO, TCRT, BEAT, and APRN.

Sep 28, 2022 08:31 am ET

HeartBeam Granted Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the United States Patent and Trademark Office. The innovation opens the pathway for a patient to record a set of signals using HeartBeam AIMIGo outside of a medical setting with a diagnostic synthesized 12-lead ECG immediately transmitted to a physician for review and diagnos

Sep 22, 2022 08:30 am ET

Thinking about buying stock in American Virtual Cloud Technologies, Spero Therapeutics, Robinhood Markets, Heartbeam, or Virtu Financial?

NEW YORK, Sept. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVCT, SPRO, HOOD, BEAT, and VIRT.

Sep 20, 2022 08:31 am ET

HeartBeam Launches New Video Showcasing the HeartBeam AIMI™ and AIMIGo™ Technologies

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced that in conjunction with an upcoming virtual roadshow webinar taking place Tuesday, September 20, 2022, at 4:30 p.m. ET, it has released a new video that takes viewers behind the scenes for a featured look at the HeartBeam AIMIGo technology and will be shown to viewers of the webcast.

Sep 15, 2022 10:55 am ET

Thinking about buying stock in Heartbeam, Akerna, CSX Corp, Rivian Automotive, or Xpeng?

NEW YORK, Sept. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BEAT, KERN, CSX, RIVN, and XPEV.

Sep 15, 2022 08:31 am ET

HeartBeam Granted Patent for 12-Lead Electrocardiogram (ECG) Patch Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent for a 12-lead electrocardiogram (ECG) patch monitor intended for detection of acute coronary syndrome (ACS) and cardiac arrhythmia was issued by the United States Patent and Trademark Office. The innovation builds on HeartBeam’s growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting.

Sep 12, 2022 08:31 am ET

HeartBeam to Host Virtual Roadshow Webinar on Tuesday September 20, 2022 at 4:30 p.m. Eastern Time

Aug 16, 2022 08:42 am ET

HeartBeam Announces FDA Submission of HeartBeam AIMI™ Product

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its HeartBeam AIMI™ platform technology for use in diagnosing heart attacks.

Aug 11, 2022 04:01 pm ET

HeartBeam Reports Second Quarter 2022 Financial Results

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, has reported its financial and operational results for the second quarter ended June 30, 2022.

Aug 04, 2022 08:45 am ET

HeartBeam Names Ken Persen as Chief Technology Officer

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, announced today the appointment of Ken Persen to the role of Chief Technology Officer. Persen has extensive technology, executive and start-up experience in healthcare and cardiac device industries. He will lead the overall technology strategy and development of the HeartBeam AIMI™ and HeartBeam AIMIGo™ platforms.

Jul 28, 2022 08:31 am ET

HeartBeam Wins CVI 2022 Innovation Summit Award

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, was selected as winner of the annual Cardiovascular Innovations (CVI) 2022 Innovation Summit and Shark Tank Competition held on July 21, 2022, in Denver, Colorado. The CVI annual conference focuses on innovative health solutions for cardiology clinicians who participate in the care of patients with coronary, peripheral and structural cardiovascular diseases.

Jul 26, 2022 08:31 am ET

HeartBeam to Host Second Quarter 2022 Results Conference Call on Thursday August 11, 2022 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, will hold a conference call on Thursday August 11, 2022 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2022, and will be reviewing recent announcements, ongoing initiatives and key 2022 milestones. A press release detailing these results will be issued prior to the call.

Jun 30, 2022 08:31 am ET

HeartBeam Expands Patient Population for Emergency Department Software Technology Solution

May 25, 2022 08:31 am ET

HeartBeam to Present at LD Micro Invitational XII Conference on June 7, 2022

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, will present at the in-person LD Micro Invitational XII Conference being held at the Four Seasons in Westlake Village, CA on June 7 – 9, 2022.

May 18, 2022 08:31 am ET

HeartBeam to Participate in the H.C. Wainwright Global Investment Conference May 23-26, 2022

May 12, 2022 04:01 pm ET

HeartBeam Reports First Quarter 2022 Financial Results

Apr 28, 2022 08:31 am ET

HeartBeam to Host First Quarter 2022 Results Conference Call on Thursday May 12, 2022 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, will hold a conference call on Thursday May 12, 2022 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2022, and will be reviewing recent announcements, ongoing initiatives and key 2022 milestones. A press release detailing these results will be issued prior to the call.

Apr 19, 2022 04:01 pm ET

HeartBeam to Host Virtual Roadshow Webinar on Wednesday April 27, 2022 at 11:30 a.m. Eastern Time

Mar 24, 2022 04:01 pm ET

HeartBeam Reports Fourth Quarter and Full Year 2021 Financial Results

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary Electrocardiogram (“ECG”) telemedicine technology for heart attack detection, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2021.

Mar 10, 2022 08:31 am ET

HeartBeam Partners with Triple Ring Technologies to Co-Develop Telehealth Solution Device

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has signed a professional services agreement (the “Agreement”) with Triple Ring Technologies, Inc. (“Triple Ring”), a co-development company, to assist in the design and development of its Telehealth complete solution 3D vector Electrocardiogram (ECG) collection device for remote heart attack or myocardial infarction (MI) monitoring. The joint partnership is a five-phase expedited device development project schedul

Mar 07, 2022 08:31 am ET

HeartBeam to Host Fourth Quarter and Full Year 2021 Results Conference Call on Thursday, March 24, 2022 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, will hold a conference call on Thursday, March 24, 2022 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2021, and will be reviewing recent announcements, ongoing initiatives and key 2022 milestones. A press release detailing these results will be issued prior to the call.

Mar 02, 2022 08:31 am ET

HeartBeam Partners with Phoebe Putney Health System for First Pilot Study of Emergency Department Myocardial Infarction Software

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has signed a Business Associate Agreement (BAA) and Clinical Trial Agreement (CTA) with Phoebe Putney Health System to conduct a pilot study designed to evaluate HeartBeam’s Emergency Department (ED) Myocardial Infarction (MI) software product.

Feb 02, 2022 05:21 pm ET

HeartBeam Partners with LIVMOR for Cloud Based Remote Monitoring Portal

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has signed a partnership agreement with LIVMOR Inc., a digital health solutions company, to build a HeartBeam branded version of LIVMOR’s Halo+ FDA cleared turnkey solution for remote patient monitoring (“RPM”) to connect physicians and patients.

Jan 27, 2022 09:42 am ET

HeartBeam Establishes Scientific Advisory Board and Appoints C. Michael Gibson, MD as Chairman

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, today announced the establishment of a Scientific Advisory Board (SAB) to provide scientific guidance and insight to the Company’s medical studies, research and product pipelines. In conjunction, world-renowned cardiologist C. Michael Gibson, MS, MD, was appointed as Chairman of the new SAB.

Dec 29, 2021 08:31 am ET

HeartBeam to Participate in the H.C. Wainwright BIOCONNECT Conference

Dec 22, 2021 08:31 am ET

HeartBeam Appoints Alan Baumel as Chief Operating Officer

Dec 16, 2021 04:01 pm ET

HeartBeam Reports Third Quarter and Nine Months 2021 Financial Results

Nov 17, 2021 08:31 am ET

HeartBeam Announces Closing of Initial Public Offering

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, today announced the closing of its underwritten initial public offering of 2,750,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $6.00. The common stock and warrants were issued separately in this offering. The warrants have an exercise price of $6.00 per share and are exercisable for a period of five

Nov 10, 2021 10:10 pm ET

HeartBeam Announces Pricing of $16.5 Million Initial Public Offering

HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, today announced the pricing of its initial public offering of 2,750,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $6.00. The warrants have an exercise price of $6.00 per share and are exercisable for a period of five years after the issuance date. All units are being offered by HeartBeam, Inc. In add

Feb 02, 2021 05:50 pm ET

Investors Bancorp Set to Join S&P SmallCap 600

NEW YORK, Feb. 2, 2021 /PRNewswire/ -- Investors Bancorp Inc. (NASD: ISBC) will replace BioTelemetry Inc. (NASD: BEAT) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 10. Koninklijke Philips N.V. (NYSE: PHG) is acquiring BioTelemetry in a deal expected to be completed soon pending final conditions.

Jan 07, 2021 01:55 pm ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ALXN, MGLN, FLIR, BEAT; Shareholders Are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concerning potential violations of the federal securities laws and/or breaches of fiduciary...

Jan 07, 2021 10:09 am ET

Moore Kuehn Encourages TNAV, ATAC, BEAT, and FTIV Investors to Contact Law Firm

Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek...

Jan 05, 2021 10:28 am ET

ALERT: Halper Sadeh LLP Investigates TDY, TCP, BEAT, HCAP, SNSS; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Jan 05, 2021 09:49 am ET

Moore Kuehn Encourages BEAT, MGLN, RLH, and ELY Investors to Contact Law Firm

NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:

Dec 28, 2020 07:15 pm ET

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - PS, BEAT, HCAP, NEOS, HBAN

NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Dec 27, 2020 11:50 pm ET

CORRECTING and REPLACING BIOTELEMETRY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioTelemetry, In

Please replace the release dated December 23, 2020 with the following corrected version due to multiple revisions.

Dec 24, 2020 10:49 pm ET

Lifshitz Law Firm, P.C. Announces Investigation of ANCN, BEAT, HMSY, SNCA, SPWH, TCP, TRP, TLRY, and APHA

NEW YORK, Dec. 24, 2020 /PRNewswire/ --

Dec 22, 2020 08:00 am ET

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies – BEAT, HBAN, PS, CKH

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: BioTelemetry, Inc. (NASDAQ: BEAT) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...

Dec 21, 2020 11:00 am ET

Moore Kuehn Encourages BEAT, AJRD, ANCN, and RNET Investors to Contact Law Firm

Dec 19, 2020 03:11 pm ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - BEAT, SNCA, BBIO, TLRY, NEOS

NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Dec 18, 2020 09:00 pm ET

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioTelemetry, Inc.

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioTelemetry, Inc. ("BioTelemetry" or the "Company") (NASDAQ: BEAT) in connection with the proposed acquisition of the Company by Royal Philips (NYSE: PHG). The transaction is structured as an all-cash tender offer in which the Company's shareholders will receive only $72.00 for each share of BioTelemetry common stock that they hold.

Dec 18, 2020 08:00 pm ET

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of BioTelemetry, Inc. - BEAT

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating BioTelemetry, Inc. ("BEAT" or the "Company") (BEAT) relating to its proposed acquisition by Royal Phillips. Under the terms of the agreement, BEAT shareholders will receive $72.00 in cash per share.

Dec 18, 2020 07:06 pm ET

(BEAT) Alert: Johnson Fistel Investigates Proposed Sale of BioTelemetry; Is $72 a Fair Price?

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of BioTelemetry, Inc. (NASDAQ: BEAT) breached their fiduciary duties in connection with the proposed sale of the Company to Royal Philips...

Dec 18, 2020 03:30 pm ET

BIOTELEMETRY ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BEAT and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of BioTelemetry, Inc. (NASDAQ: BEAT) breached their fiduciary duties or violated the federal securities...

Dec 18, 2020 01:17 pm ET

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of BioTelemetry, Inc.

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by BioTelemetry, Inc. (NASDAQ: BEAT) and its board of directors concerning the proposed acquisition of the company by Royal Philips (NYSE: PHG). Stockholders will receive $72.00 for each share of BioTelemetry stock that they hold. The transaction is valued at approximately $2.8 billion and is expected to close in the first quarter of 2021.

Dec 18, 2020 10:09 am ET

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BioTelemetry, Inc. Buyout

Rigrodsky & Long, P.A. announces that it is investigating BioTelemetry, Inc. (“BioTelemetry”) (NASDAQ GS: BEAT) regarding possible breaches of fiduciary duties and other violations of law related to BioTelemetry’s agreement to be acquired by Royal...

Dec 18, 2020 09:03 am ET

BioTelemetry Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of BioTelemetry, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – BEAT

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of BioTelemetry, Inc. (NASDAQ: BEAT) to Royal Philips for $72.00 per share in cash is fair to BioTelemetry shareholders.

Dec 18, 2020 07:51 am ET

(BEAT) Alert: Johnson Fistel Investigates Proposed Sale of BioTelemetry; Is $72 a Fair Price?

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of BioTelemetry, Inc. (NASDAQ: BEAT) breached their fiduciary duties in connection with the proposed sale of the Company to Royal Philips (NYSE: PHG, AEX: PHIA).

Dec 18, 2020 02:50 am ET

Philips to Acquire BioTelemetry

BioTelemetry, Inc. (NASDAQ: BEAT) , the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that they have entered into a definitive merger...

Oct 29, 2020 04:05 pm ET

BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended September 30, 2020....

Oct 22, 2020 04:05 pm ET

BioTelemetry, Inc. to Release Third Quarter 2020 Earnings Results on October 29, 2020

BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2020 earnings on Thursday, October 29 at 4:00 PM Eastern Time. BioTelemetry, Inc. will host an earnings conference call on Thursday, October 29, at 5:00 PM Eastern Time. The call...

Jul 30, 2020 04:05 pm ET

BioTelemetry, Inc. Reports Second Quarter 2020 Financial Results

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended June 30, 2020....

Jul 30, 2020 07:00 am ET

BioTelemetry, Inc. Announces Sales Agent Agreement with Boston Scientific Corporation

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced a sales agent agreement with Boston Scientific...

Jul 29, 2020 08:00 am ET

BioTelemetry, Inc. Acquires Remote Patient Monitoring Platform from Centene Subsidiary

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced it has acquired the On.Demand™ remote patient...

Jul 23, 2020 04:05 pm ET

BioTelemetry, Inc. to Release Second Quarter 2020 Earnings Results on July 30, 2020

BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2020 earnings on Thursday, July 30 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Thursday, July 30, 2020. The broadcast...

May 06, 2020 04:05 pm ET

BioTelemetry, Inc. Reports First Quarter 2020 Financial Results

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended March 31, 2020. Quarter...

Apr 29, 2020 01:13 pm ET

BioTelemetry, Inc. to Release First Quarter 2020 Earnings Results on May 6, 2020

BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2020 earnings on Wednesday, May 6 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Wednesday, May 6, 2020. The broadcast will...

Apr 27, 2020 09:05 am ET

BioTelemetry, Inc. to Move to Virtual-only Annual Stockholder Meeting for 2020

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that its 2020 Annual Meeting of Stockholders will be...

Apr 07, 2020 10:29 am ET

BioTelemetry, Inc. Names Dr. Andrei Stoica Chief Technology Officer

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Dr. Andrei Stoica has been named Chief Technology...

Mar 25, 2020 09:21 am ET

BIOTELEMETRY, INC. EXPANDS MCOT™ SERVICE TO MONITOR LIFE-THREATENING QT PROLONGATION IN COVID-19 PATIENTS

BioTelemetry, Inc. (NASDAQ:BEAT), a leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced the activation of an expanded service using its Mobile...

Feb 26, 2020 04:05 pm ET

BioTelemetry, Inc. Reports Fourth Quarter 2019 Financial Results

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter and year ended December 31,...

Feb 18, 2020 04:05 pm ET

BioTelemetry, Inc. to Release Fourth Quarter 2019 Earnings Results on February 26, 2020

BioTelemetry, Inc. (NASDAQ:BEAT) will release its fourth quarter 2019 earnings on Wednesday, February 26 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Wednesday, February 26, 2020. The...

Nov 05, 2019 04:05 pm ET

BioTelemetry, Inc. Reports Third Quarter 2019 Financial Results

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the third quarter ended September 30, 2019....

Oct 29, 2019 02:54 pm ET

BioTelemetry, Inc. to Release Third Quarter 2019 Earnings Results on November 5, 2019

BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2019 earnings on Tuesday, November 5 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, November 5, 2019. The broadcast...

Sep 03, 2019 04:05 pm ET

BioTelemetry, Inc. Named to Fortune Magazine’s 100 Fastest-Growing Companies List

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today it has been ranked 31st on Fortune Magazine’s 100...

Aug 05, 2019 12:07 pm ET

BioTelemetry, Inc. Names Manish Wadhwa, M.D., F.H.R.S. Chief Medical Officer

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Manish Wadhwa, M.D., F.H.R.S. (Fellow of the...

Jul 30, 2019 04:05 pm ET

BioTelemetry, Inc. Reports Second Quarter 2019 Financial Results

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the second quarter ended June 30, 2019....

Jul 24, 2019 08:30 am ET

BioTelemetry, Inc. Acquires Sweden-based ADEA Medical AB and Expands International Service Offering

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that it has acquired ADEA Medical AB, an early-stage...

Jul 19, 2019 05:58 pm ET

BioTelemetry, Inc. to Release Second Quarter 2019 Earnings Results on July 30, 2019

BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2019 earnings on Tuesday, July 30 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, July 30, 2019. The broadcast...

Jun 04, 2019 07:30 am ET

Itamar Medical and BioTel Heart, a Division of BioTelemetry, Expand Collaboration to Offer Itamar’s Total Sleep Solution™ to BioTel Heart Cardiology Customers

Itamar Medical Ltd. (NASDAQ and TASE:ITMR), a company that develops, manufacturers and markets non-invasive diagnostic devices for sleep apnea with a focus on the cardiology market, and BioTel Heart, a division of BioTelemetry, Inc. (NASDAQ:BEAT),...

May 15, 2019 01:52 pm ET

BioTelemetry President and CEO Joseph H. Capper Named Healthcare CEO of the Year at 26th Annual PACT Enterprise Awards

BioTelemetry (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that Joseph H. Capper, President and CEO, has been awarded...

Apr 25, 2019 04:05 pm ET

BioTelemetry, Inc. Reports First Quarter 2019 Financial Results

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the first quarter ended March 31, 2019....

Apr 19, 2019 07:40 am ET

Research Report Identifies AK Steel Holding, BioTelemetry, MarineMax, Omnicell, Agile Therapeutics, and America's Car-Mart with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AK Steel Holding Corporation (NYSE:AKS), BioTelemetry, Inc. (NASDAQ:BEAT),...

Apr 18, 2019 01:22 pm ET

BioTelemetry, Inc. to Release First Quarter 2019 Earnings Results on April 25, 2019

BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2019 earnings on Thursday, April 25 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Thursday, April 25, 2019. The broadcast...

Mar 04, 2019 08:30 am ET

BioTelemetry, Inc. Completes Acquisition of Geneva Healthcare, Inc.

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that the Company has completed its acquisition of...

Feb 28, 2019 08:30 am ET

BioTelemetry, Inc. Elects Laura Dietch and Tiffany Olson to its Board of Directors

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today the election of Laura Dietch and Tiffany Olson to...

Feb 21, 2019 04:05 pm ET

BioTelemetry, Inc. Reports Fourth Quarter 2018 Financial Results

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter ended December 31, 2018....

Feb 11, 2019 04:52 pm ET

BioTelemetry, Inc. to Release Fourth Quarter 2018 Earnings Results on February 21, 2019

BioTelemetry, Inc. (NASDAQ:BEAT) will release its fourth quarter 2018 earnings on Thursday, February 21 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Thursday, February 21, 2019. The...

Jan 29, 2019 07:45 am ET

Investor Expectations to Drive Momentum within Dollar General, Zayo Group, Cabot Oil & Gas, Sangamo Therapeutics, BioTelemetry, and Dean Foods — Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dollar General Corporation (NYSE:DG), Zayo Group Holdings, Inc....

Jan 28, 2019 08:30 am ET

BioTelemetry, Inc. to Acquire Geneva Healthcare, Inc.

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, and Geneva Healthcare, Inc. (“Geneva”), the leading...

Dec 11, 2018 07:40 am ET

Report: Exploring Fundamental Drivers Behind GTT Communications, Midstates Petroleum, Arsanis, BioTelemetry, Dolby Laboratories, and Northern Dynasty Minerals — New Horizons, Emerging Trends, and Upco

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of GTT Communications, Inc. (NYSE:GTT), Midstates Petroleum Co. (NYSE:MPO),...

Nov 07, 2018 04:49 pm ET

BioTelemetry, Inc. Elects Stephan Rietiker to its Board of Directors

BioTelemetry, Inc. (NASDAQ:BEAT) announced today that Stephan Rietiker has been elected to BioTelemetry’s Board of Directors. Dr. Rietiker was most recently the Chief Executive Officer of LifeWatch AG, until it was acquired by BioTelemetry in...

Nov 02, 2018 08:45 am ET

New Research: Key Drivers of Growth for FleetCor Technologies, Materion, BioTelemetry, Northrop Grumman, Taubman Centers, and Sabre — Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of FleetCor Technologies, Inc. (NYSE:FLT), Materion Corporation...

Oct 30, 2018 04:05 pm ET

BioTelemetry, Inc. Reports Third Quarter 2018 Financial Results

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the third quarter ended...

Oct 18, 2018 07:02 pm ET

BioTelemetry, Inc. to Release Third Quarter 2018 Earnings Results on October 30, 2018

BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2018 earnings on Tuesday, October 30 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, October 30, 2018. The...

Oct 11, 2018 07:30 am ET

Market Trends Toward New Normal in Altra Industrial Motion, IDEXX Laboratories, BioTelemetry, Galectin Therapeutics, NETGEAR, and Merck & Co. — Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Altra Industrial Motion Corp. (NASDAQ:AIMC), IDEXX Laboratories, Inc....

Aug 06, 2018 08:00 am ET

Analysis: Positioning to Benefit within BioTelemetry, Genworth Financial, Power Integrations, Phibro Animal Health, BlackRock, and The ExOne — Research Highlights Growth, Revenue, and Consolidated Res

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BioTelemetry, Inc. (NASDAQ:BEAT), Genworth Financial, Inc. (NYSE:GNW),...

Jul 25, 2018 04:09 pm ET

BioTelemetry, Inc. Reports Second Quarter 2018 Financial Results

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the second quarter ended...

Jul 17, 2018 07:00 am ET

BioTelemetry, Inc. to Release Second Quarter 2018 Earnings Results on July 25, 2018

BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2018 earnings on Wednesday, July 25 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Wednesday, July 25, 2018. The broadcast...

Jun 13, 2018 08:05 am ET

BioTel Care, a BioTelemetry Company, Announces Release of Next-Generation Wireless Blood Glucose Monitor

(NASDAQ:BEAT) – BioTel CareTM (formally known as Telcare), a BioTelemetry company, announced today the release of its next-generation wireless blood glucose monitor for diabetes management. As an industry pioneer, BioTel Care developed the...

Apr 27, 2018 07:30 am ET

Consolidated Research: 2018 Summary Expectations for AdvanSix, Flagstar, CalAmp, Agree Realty, Cowen Group, and BioTelemetry — Fundamental Analysis, Key Performance Indications

NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AdvanSix Inc. (NYSE:ASIX), Flagstar Bancorp, Inc....

Apr 25, 2018 04:05 pm ET

BioTelemetry, Inc. Reports First Quarter 2018 Financial Results

Company Exceeds Revenue and Adjusted EBITDA Expectations

Apr 19, 2018 10:37 am ET

BioTelemetry, Inc. to Release First Quarter 2018 Earnings Results on April 25, 2018

MALVERN, Pa., April 19, 2018 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2018 earnings on Wednesday, April 25 at 4:00 PM Eastern Time.

Mar 23, 2018 02:59 pm ET

BioTelemetry, Inc. (Nasdaq: BEAT) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its 10th Listing Anniversary

ADVISORY, March 23, 2018 (GLOBE NEWSWIRE) --

Mar 01, 2018 07:45 am ET

Analysis: Positioning to Benefit within Bluerock Residential Growth REIT, National Presto Industries, Healthways, Deluxe, BioTelemetry, and Modine Manufacturing — Research Highlights Growth, Revenue,

NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bluerock Residential Growth REIT, Inc. (NYSE:BRG),...

Feb 22, 2018 04:05 pm ET

BioTelemetry, Inc. Reports Fourth Quarter 2017 Financial Results

Company Delivers Record Revenue and Adjusted EBITDA Exceeds Expectations

Feb 12, 2018 05:41 pm ET

BioTelemetry, Inc. to Release Fourth Quarter 2017 Earnings Results on February 22, 2018

MALVERN, Pa., Feb. 12, 2018 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its fourth quarter 2017 earnings on Thursday, February 22nd at 4:00 PM Eastern Time.

Jan 04, 2018 08:30 am ET

Analysis: Positioning to Benefit within FleetCor Technologies, Zogenix, BioTelemetry, Modine Manufacturing, Navigant Consulting, and CalAmp — Research Highlights Growth, Revenue, and Consolidated Resu

NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FleetCor Technologies, Inc. (NYSE:FLT), Zogenix, Inc....

Nov 30, 2017 09:27 am ET

BioTelemetry, Inc. Enters Agreement to Provide Cardiac Monitoring for Apple’s Heart Study

MALVERN, Pa., Nov. 30, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today...

Nov 27, 2017 04:05 pm ET

Telcare, a Division of BioTelemetry, Inc., Announces Collaboration with Onduo in Diabetes Management Program

MALVERN, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- (NASDAQ:BEAT) – Telcare, the manufacturer of the world’s first FDA-cleared cellular-enabled blood glucose monitor, has entered into a strategic collaboration with Onduo, a joint venture created by Verily (an Alphabet...

Nov 07, 2017 04:05 pm ET

BioTelemetry, Inc. Reports Third Quarter 2017 Financial Results

Company Posts Strong Growth with Integration Ahead of Schedule Reports Record Quarterly Revenue and Adjusted EBITDA...

Nov 07, 2017 04:05 pm ET

BioTelemetry, Inc. Reports Third Quarter 2017 Financial Results

Company Posts Strong Growth with Integration Ahead of Schedule Reports Record Quarterly Revenue and Adjusted EBITDA

Oct 30, 2017 06:40 pm ET

BioTelemetry, Inc. to Release Third Quarter 2017 Earnings Results on November 7, 2017

MALVERN, Pa., Oct. 30, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2017 earnings on Tuesday, November 7th at 4:00 PM Eastern Time....

Aug 08, 2017 04:05 pm ET

BioTelemetry, Inc. Reports Second Quarter 2017 Financial Results

Reports Record Quarterly Revenue and EBITDA ...

Jul 07, 2017 08:30 am ET

BioTelemetry, Inc. Reaches a Final Milestone in Acquisition of LifeWatch AG

MALVERN, Pa. and ZUG, Switzerland, July 07, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today the definitive results of the tender offer for LifeWatch AG (SIX:LIFE) which concluded on June 28, 2017. The definitive results show shareholders have tendered 17,848,661 shares of LifeWatch, representing approximately 97% of the total shares outstanding. ...

May 23, 2017 08:15 am ET

BioTelemetry, Inc. Announces Extension of the Tender Offer Period for LifeWatch AG Shares

MALVERN, Pa., May 23, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that, in accordance with the provisions of the Offer Prospectus and at the Company’s request, the Swiss Takeover Board has extended the initial main offer period of the tender offer to acquire all of the shares of LifeWatch AG (SIX:LIFE), which was scheduled to expire at 4:00 p.m. CEST, on May 23, 2017. The offer period, which has been extended five tr...

May 10, 2017 08:30 am ET

BioTelemetry, Inc. Announces the Start of the Tender Offer Period for LifeWatch AG Shares

MALVERN, Pa. and ZUG, Switzerland, May 10, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today the start of the main offer period of the tender offer to acquire all of the shares of LifeWatch AG (SIX:LIFE). The main offer period is scheduled to expire at 4:00 p.m. CEST, on May 23, 2017. It will be open for a period of ten trading days. The settlement of the tender offer is subject to regulatory approvals and other customar...

May 03, 2017 04:05 pm ET

BioTelemetry, Inc. Reports First Quarter 2017 Financial Results

MALVERN, Pa., May 03, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the first quarter ended March 31, 2017....

Apr 25, 2017 03:50 pm ET

BioTelemetry, Inc. to Release First Quarter 2017 Earnings Results on May 3, 2017

MALVERN, Pa., April 25, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2017 earnings on Wednesday, May 3, 2017 at 4:00 PM Eastern Time....

Apr 24, 2017 05:00 pm ET

BioTelemetry, Inc. Issues Prospectus for Public Tender Offer to Acquire LifeWatch AG

MALVERN, Pa. and ZUG, Switzerland, April 24, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) and LifeWatch AG (SIX:LIFE) announced today that BioTelemetry published the prospectus for the public tender offer for all publicly held registered shares of LifeWatch AG. Shareholders of LifeWatch will receive either CHF10.00 in cash and 0.1457 shares of BioTelemetry stock (“Main Offer Consideration”) (equivalent to CHF4.00 per LifeWatch share based on the closing price of BioTelemetry on Friday, April 7, 2017) or CHF8.00 in cash and 0.2185 shares of BioTelemetry stock (“Alternative Offer...

Feb 22, 2017 04:05 pm ET

BioTelemetry, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results

MALVERN, Pa., Feb. 22, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter and full year ended December 31, 2016....

Feb 06, 2017 08:05 am ET

Sprint & BioTelemetry, Inc. Receive a 2017 IoT Evolution Business Impact Award

OVERLAND PARK, Kan., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Sprint (NYSE:S) announced today that a 2017 IoT Evolution Business Impact Award will be presented to Sprint and its client, BioTelemetry, Inc., by TMC and Crossfire Media at the IoT Evolution Conference & Expo on February 9, 2017. Sprint and BioTelemetry will present the winning case at the Expo....

Oct 24, 2016 03:29 pm ET

BioTelemetry, Inc. to Release Third Quarter 2016 Earnings Results on November 2, 2016

MALVERN, Pa., Oct. 24, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2016 earnings on Wednesday, November 2, 2016 at 4:00 PM Eastern Time....

Aug 29, 2016 10:14 am ET

BioTelemetry, Inc. announces CE mark approval of Holter analysis software

MALVERN, Pa., Aug. 29, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that the Company has received CE mark approval of its Holter analysis software. The software can be used either on a stand-alone basis or in combination with the Company’s family of digital Holter recorders. ...

Aug 23, 2016 08:15 am ET

BioTelemetry, Inc. Agrees to License Proprietary Technology to Bloom Technologies, Inc. for Use in Prenatal Market

MALVERN, Pa., Aug. 23, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that it has entered into a strategic partnership with Bloom Technologies, Inc. (“Bloomlife”), an early stage digital health company. Under the terms of the agreement, Bloomlife will pay BioTelemetry a percentage of revenue to license their proprietary telemetry technology to commercialize a consumer oriented prenatal health sensor. This sens...

Aug 02, 2016 04:05 pm ET

BioTelemetry, Inc. Reports Second Quarter 2016 Financial Results

MALVERN, Pa., Aug. 02, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the second quarter ended June 30, 2016....

Jul 26, 2016 04:15 pm ET

BioTelemetry, Inc. to Release Second Quarter 2016 Earnings Results on August 2, 2016

MALVERN, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2016 earnings on Tuesday, August 2, 2016 at 4:00 PM Eastern Time....

Jul 26, 2016 08:30 am ET

BioTelemetry, Inc. Announces FDA Approval of Its Next Generation Device, the MCOT™ Patch

MALVERN, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance of its next generation Mobile Cardiac Outpatient Telemetry™ device, the MCOT™ Patch. The MCOT™ Patch is a four-lead, two-channel system which provides the same best in class technology as the current MCOT™, in a more convenient form factor. The MCOT™ devices, thr...

Jul 25, 2016 07:41 pm ET

MB Financial to Join S&P MidCap 400; BioTelemetry and Raven Industries to Join S&P SmallCap 600

NEW YORK, July 25, 2016 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices after the close of trading on Friday, July 29:

Jul 20, 2016 08:45 am ET

BioTelemetry, Inc. Announces Its Latest Success in Patent Enforcement

MALVERN, Pa., July 20, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that the District Court in the District of Massachusetts has entered a July 14, 2016 Consent Judgment permanently enjoining and restraining InfoBionic, Inc. (“InfoBionic”) from “making, using, offering to sell, or selling within the United States or importing into the United States” any of its “First-Generation” MoMe® Kardia system and from “e...

May 11, 2016 09:25 am ET

BioTelemetry, Inc. Announces the Completion of Its Acquisition of VirtualScopics, Inc.

MALVERN, Pa., May 11, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that it has completed its acquisition of VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions. The acquisition comes after the successful completion of the all cash tender offer for all outstanding common and preferred shares of VirtualScopics. The total purchase consideration was approximately $15.0 million, net ...

May 10, 2016 08:05 am ET

BioTelemetry, Inc. Announces Results of Tender Offer for Shares of VirtualScopics, Inc.

MALVERN, Pa., May 10, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ: BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that the tender offer of its wholly owned subsidiary, BioTelemetry Research Acquisition Corporation (“Offeror”), to purchase all outstanding common and preferred shares of VirtualScopics, Inc. (“VirtualScopics”); (NASDAQ:VSCP) at an offer price of $4.05 per share for VirtualScopics’ common stock, $336.30 per share for VirtualScopics’ Series A and Ser...

May 09, 2016 10:00 am ET

VirtualScopics, Inc. Board Determines Gastineau Partners Proposal Not Reasonably Expected to Lead to a Superior Company Proposal

ROCHESTER, N.Y., May 9, 2016 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, announced today that its Board of Directors, in consultation with its legal and financial advisors, has determined that an unsolicited proposal from a group identifying itself as Gastineau Partners, LLC, to acquire an uncertain number of shares of the Company's outstanding common and preferred stock and purchase newly issued preferred stock at an undetermined price and unspecified rights, preferences and privileges, would not reasonably be expected to lead

May 06, 2016 04:05 pm ET

BioTelemetry, Inc. Appoints Colin Hill to Its Board of Directors

MALVERN, Pa., May 06, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today the appointment of Colin Hill to its Board of Directors....

Mar 29, 2016 09:50 am ET

VirtualScopics, Inc. Cancels Conference Call Due To Recent Announcement Of The Definitive Agreement With BioTelemetry, Inc.

ROCHESTER, N.Y., March 29, 2016 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, today announced it will not hold its conference call, or provide its webcast, previously scheduled for Wednesday, March 30, 2016 at 8:30 a.m. ET.

You are here

Heartbeam, Inc. - Common Stock (OQ:BEAT)

Business Focus: N/A